Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Shionogi & Co Ltd    4507   JP3347200002

SHIONOGI & CO LTD

(4507)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

GSK's two-drug HIV Dovato treatment meets main goal in study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/16/2019 | 12:40pm EDT
FILE PHOTO: The GSK logo is seen on top of GSK Asia House in Singapore

(This July 10 story corrects to show patients switched from Gilead's Descovy, not Gilead's Vemlidy, in fifth paragraph)

(Reuters) - GlaxoSmithKline Plc two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial, the drugmaker said on Wednesday.

Dovato, a combination of dolutegravir and lamivudine, was approved in the United States in April for newly-diagnosed patients, boosting the British drugmaker's prospects against Gilead Sciences Inc, which currently leads the HIV treatment market.

Liberium analyst Graham Doyle said the study results will add to the data package supporting Dovato as GSK aims to convince doctors that two drug therapies are just as effective as triple therapies.

GSK is betting that a shift to using two drugs rather than three will boost its sales by offering patients a therapy with fewer potentially toxic side effects.

The study evaluated the effectiveness of Dovato, a combination of dolutegravir and lamivudine, in adults with the HIV-1 virus who switched to the regimen from at least a triple combination containing Gilead Sciences Descovy, the British company's HIV drugs division ViiV said.

ViiV also said adults who used Dovato did not develop any resistance to the treatment.

GSK already has a two-drug regimen Juluca on the market, but only for HIV patients that have received prior treatment.

Pfizer Inc and Shionogi & Co Ltd also have small stakes in ViiV, which accounted for about 39% of GSK's group operating profit last year, according to UBS analysts.

The HIV-1 category has the most widespread strains of the virus, which severely affects the body's immune system.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)

Stocks mentioned in the article
ChangeLast1st jan.
GILEAD SCIENCES -0.20% 64.91 Delayed Quote.3.77%
GLAXOSMITHKLINE 0.40% 1653 Delayed Quote.10.96%
PFIZER 0.12% 42.82 Delayed Quote.-2.02%
SHIONOGI & CO LTD 1.66% 6231 End-of-day quote.0.91%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHIONOGI & CO LTD
07/22SHIONOGI : Notice of Completion of Disposal of Treasury Shares as Restricted Sto..
AQ
07/18SHIONOGI : Notice of Completion of Disposal of Treasury Shares as Restricted Sto..
PU
07/16As steep patent cliff looms, Shionogi moves to develop its own U.S. sales sta..
RE
07/16GSK's two-drug HIV Dovato treatment meets main goal in study
RE
06/23SHIONOGI : Concludes Licensing Agreements with Eddingpharm and EOC Pharma for Lu..
PU
06/20SHIONOGI : And ferrer conclude a contract for the promotion in spain of rizmoic,..
AQ
06/19SHIONOGI : Announcement about the Adjustment of the Conversion Value for Euro-Ye..
AQ
06/19SHIONOGI : Got Approval of Additional Indication of INTUNIV in Japan for Treatme..
AQ
06/19SHIONOGI : to Present Cefiderocol and COT-143 Data at American Society for Micro..
AQ
06/19SHIONOGI : And ferrer conclude a contract for the promotion in spain of rizmoic®..
PU
More news
Financials (JPY)
Sales 2020 362 B
EBIT 2020 144 B
Net income 2020 130 B
Finance 2020 430 B
Yield 2020 1,60%
P/E ratio 2020 14,8x
P/E ratio 2021 14,3x
EV / Sales2020 4,20x
EV / Sales2021 3,81x
Capitalization 1 950 B
Chart SHIONOGI & CO LTD
Duration : Period :
Shionogi & Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIONOGI & CO LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 7 280,00  JPY
Last Close Price 6 262,00  JPY
Spread / Highest target 40,5%
Spread / Average Target 16,3%
Spread / Lowest Target 2,20%
EPS Revisions
Managers
NameTitle
Isao Teshirogi President & Representative Director
Motozo Shiono Chairman
Kohji Hanasaki Manager-Accounting & Finance
Akio Nomura Independent Director
Teppei Mogi Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SHIONOGI & CO LTD0.91%18 008
JOHNSON & JOHNSON-0.32%345 980
PFIZER-1.90%237 451
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
NOVARTIS24.78%216 273